<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Pediatr Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">J Pediatr Neurosci</journal-id>
<journal-id journal-id-type="publisher-id">JPN</journal-id>
<journal-title-group>
<journal-title>Journal of Pediatric Neurosciences</journal-title>
</journal-title-group>
<issn pub-type="ppub">1817-1745</issn>
<issn pub-type="epub">1998-3948</issn>
<publisher>
<publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name>
<publisher-loc>India</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29899766</article-id>
<article-id pub-id-type="pmc">5982487</article-id>
<article-id pub-id-type="publisher-id">JPN-13-13</article-id>
<article-id pub-id-type="doi">10.4103/JPN.JPN_160_16</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Actual Insights into Treatable Inborn Errors of Metabolism Causing Epilepsy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Mastrangelo</surname>
<given-names>Mario</given-names>
</name>
<xref ref-type="aff" rid="aff1"></xref>
<xref ref-type="corresp" rid="cor1"></xref>
</contrib>
</contrib-group>
<aff id="aff1">Department of Pediatrics, Child Neurology and Psychiatry-Division of Pediatric Neurology-Sapienza University of Rome, Rome, Italy</aff>
<author-notes>
<corresp id="cor1"><bold><italic>Address for correspondence: </italic></bold> Dr. Mario Mastrangelo, Via dei Sabelli 108, 00188, Rome, Italy. Phone: +39649972939; fax: +3964440232. E-mail: <email xlink:href="mario.mastrangelo@uniroma1.it">mario.mastrangelo@uniroma1.it</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<season>Jan-Mar</season>
<year>2018</year>
</pub-date>
<volume>13</volume>
<issue>1</issue>
<fpage>13</fpage>
<lpage>23</lpage>
<permissions>
<copyright-statement>Copyright: © 2018 Journal of Pediatric Neurosciences</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0">
<license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p>
</license>
</permissions>
<abstract>
<p>This review offers an update on a group of inborn errors of metabolism causing severe epilepsy with the onset in pediatric age (but also other neurological manifestations such as developmental delay or movement disorders) with available effective or potentially effective treatments. The main pathogenic and clinical features and general recommendations for the diagnostic and therapeutic workup of the following disorders are discussed: vitamin B<sub>6</sub>-dependent epilepsies, cerebral folate deficiency, congenital disorders of serine metabolism, biotinidase deficiency, inborn errors of creatine metabolism, molybdenum cofactor deficiency, and glucose transporter 1 deficiency. Available treatments are more effective on epileptic manifestations (with the possibility of complete seizure control) and motor symptoms, whereas the benefits on cognitive outcome are usually minor.</p>
</abstract>
<kwd-group>
<kwd>
<italic>Cerebral folate deficiency</italic>
</kwd>
<kwd>
<italic>epileptic encephalopathies</italic>
</kwd>
<kwd>
<italic>inborn errors of creatine metabolism</italic>
</kwd>
<kwd>
<italic>metabolic epilepsy</italic>
</kwd>
<kwd>
<italic>pyridoxine-dependent seizures</italic>
</kwd>
<kwd>
<italic>serine metabolism disorders</italic>
</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1" sec-type="intro">
<title>I<sc>NTRODUCTION</sc></title>
<p>Inborn errors of metabolism are involved in different early-onset, drug-resistant epilepsies with a prevalence ranging from 0.1 to 300 per 100,000 live births.[<xref ref-type="bibr" rid="ref1">1</xref>] In patients with suspected metabolic epilepsy, clinicians should pay a prominent attention to a group of severe but treatable or potentially treatable disorders.[<xref ref-type="bibr" rid="ref2">2</xref>] An updated picture of the most important disorders of this group is provided here. Early diagnosis and treatment of these disorders can result in the prevention of a metabolic decompensation and in the possible subsequent improvement of clinical outcome.[<xref ref-type="bibr" rid="ref1">1</xref><xref ref-type="bibr" rid="ref2">2</xref>] Available treatments are more effective on epileptic manifestations and motor symptoms, whereas benefits on cognitive outcome are generally poor.[<xref ref-type="bibr" rid="ref1">1</xref><xref ref-type="bibr" rid="ref2">2</xref>]</p>
</sec>
<sec id="sec1-2">
<title>E<sc>PILEPSIES</sc> T<sc>REATABLE WITH</sc> P<sc>YRIDOXINE OR</sc> P<sc>YRIDOXAL</sc>-5′-P<sc>HOSPHATE</sc></title>
<sec id="sec2-1">
<title><italic>ALDH7A1</italic> deficiency</title>
<p>Alpha-aminoadipic semialdehyde dehydrogenase deficiency (antiquitin) is due to mutations on <italic>ALDH7A1</italic> gene.[<xref ref-type="bibr" rid="ref3">3</xref><xref ref-type="bibr" rid="ref4">4</xref>] Antiquitin is an enzyme involved in lysine catabolism resulting in a pyridoxal-5′-phosphate (PLP) depletion [<xref ref-type="fig" rid="F1">Figure 1</xref>] and in a subsequent activation of epileptogenic mechanisms (PLP is an essential cofactor for different enzymes involved in more than 140 neuronal intracellular process). <italic>ALDH7A1</italic> deficiency is responsible for an autosomal-recessive pyridoxine-dependent epilepsy (OMIM 266100) with a prevalence ranging from 1:20,000 to 1:600,000.[<xref ref-type="bibr" rid="ref5">5</xref>] The classical clinical presentation encompasses an early-onset epileptic encephalopathy with variable seizure types and with its onset in the neonatal period or in the first months of life.[<xref ref-type="bibr" rid="ref4">4</xref>] More recently, milder epileptic phenotypes with later onset have been reported.[<xref ref-type="bibr" rid="ref4">4</xref>] Other clinical manifestations of patients with <italic>ALDH7A1</italic> deficiency include both neurological (abnormal fetal movements, signs of hypoxic ischemic encephalopathy, dystonia, increased startle response, irritability, and intellectual disability) and non-neurological (respiratory distress, abdominal distension, bilious vomiting, hepatomegaly, hypothermia, shock, and acidosis) symptoms.[<xref ref-type="bibr" rid="ref5">5</xref>]</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Metabolic pathways involved in vitamin B<sub>6</sub>-dependent seizures. Double black labels indicate the impaired steps in pyridox(am) ine-5′-phosphate oxidase (PNPO) and <italic>ALDH7A1</italic> deficiency. Antiquitin deficient or absent activity results in the accumulation of precursors α-aminoadipic semialdehyde (α-AASA) and Δ1-1-piperideine-6-carboxylate (P6C). P6C induces a Knoevenagel condensation product with the active form of pyridoxine (pyridoxal-5′-phosphate [PLP]). The above-mentioned chemical reaction removes PLP from several cellular processes. A similar PLP depletion is also produced by PNPO deficiency.</p>
</caption>
<graphic xlink:href="JPN-13-13-g001"></graphic>
</fig>
<p>Electroencephalographic patterns vary from suppression burst or hypsarrhythmia to focal or multifocal epileptic discharges.[<xref ref-type="bibr" rid="ref4">4</xref>] Possible structural brain abnormalities include hemispheric hypoplasia or atrophy, cerebellar or cortical dysplasia, intracerebral hemorrhage, or periventricular hyperintensity at magnetic resonance imaging (MRI).[<xref ref-type="bibr" rid="ref5">5</xref>]</p>
<p>A therapeutic trial with an intravenous (100 mg) or an oral/enteral (30 mg/kg/day) administration of pyridoxine can be an important step also for the diagnosis.[<xref ref-type="bibr" rid="ref4">4</xref>]</p>
<p>Intravenous administration of pyridoxine can induce a reduction of electroencephalographic abnormalities.[<xref ref-type="bibr" rid="ref5">5</xref>] This response has no diagnostic value and if it is lacking, the diagnosis cannot be excluded.[<xref ref-type="bibr" rid="ref5">5</xref>]</p>
<p>Increase of urinary α-aminoadipic semialdehyde (α-AASA), urinary or plasma α-AASA/Δ1-1-piperideine-6-carboxylate ratio, and plasma pipecolic acid can be useful biomarkers to screen the candidate patients for <italic>ALDH7A1</italic> gene sequencing.[<xref ref-type="bibr" rid="ref4">4</xref>] Other nonspecific metabolic abnormalities can be detected among plasma/cerebrospinal fluid amino acids (increase in threonine, glycine, taurine, histidine, 3-methyltyrosine, alanine, and glutamine) and neurotransmitter (decrease in gamma amino-butyric acid and increase in glutamate in cerebrospinal fluid).[<xref ref-type="bibr" rid="ref4">4</xref>]</p>
<p>Acute intravenous administration of 100 mg of pyridoxine should be followed by a long-term oral/enteral administration at the dosage of 15–30 mg/kg/day in responding patients.[<xref ref-type="bibr" rid="ref4">4</xref>] Lysine-restricted diet can represent a useful add-on therapeutic tool.[<xref ref-type="bibr" rid="ref6">6</xref>] Its mechanism of action is based on a reduced production of potentially toxic lysine catabolites.[<xref ref-type="bibr" rid="ref6">6</xref>] <sc>l</sc>
-arginine supplementation has been recently proposed as an alternative to lysine-restricted diet to support neurocognitive functions.[<xref ref-type="bibr" rid="ref7">7</xref>] The rational basis of this treatment includes a competitive inhibition of lysine transport and a subsequent reduction of accumulation of α-AASA.[<xref ref-type="bibr" rid="ref8">8</xref>] A successful <italic>ex vivo</italic> antisense treatment of an aberrant m-RNA splicing in a lymphoblast cell line of a patient carrying the mutation c.75C&gt;T opened an interesting, new perspective for the future.[<xref ref-type="bibr" rid="ref7">7</xref>] Seizures with responsiveness to folinic acid have also been described in children with mutations in <italic>ALDH7A1</italic> gene.[<xref ref-type="bibr" rid="ref9">9</xref>] The biochemical basis of this response are still unknown.[<xref ref-type="bibr" rid="ref9">9</xref>]</p>
</sec>
<sec id="sec2-2">
<title>Pyridox(am)ine 5′-phosphate oxidase deficiency</title>
<p>Pyridox(am)ine-5′-phosphate oxidase (PNPO) is the rate-limiting enzyme in the synthesis of PLP from dietary pyridoxine and pyridoxamine phosphate [<xref ref-type="fig" rid="F1">Figure 1</xref>].[<xref ref-type="bibr" rid="ref10">10</xref>] To date, PNPO-deficient activity has been associated with 17 disease-causing mutations in PNPO gene with an autosomal-recessive transmission.[<xref ref-type="bibr" rid="ref10">10</xref>]</p>
<p>PNPO deficiency (OMIM 6032870) was originally reported as a severe life-threatening neonatal encephalopathy including neonatal pyridoxine-unresponsive seizures in the first hours after birth, suppression bursts on electroencephalogram, and perinatal respiratory distress resulting in intubation in five preterm infants from three families with parental consanguinity.[<xref ref-type="bibr" rid="ref11">11</xref>] Seizures with variable semiology (prominently tonic and myoclonic) and onset (between prenatal period and the fifth month of life), dystonia, prematurity-related disorders, signs of metabolic derangement (including metabolic acidosis, hyperlactacidemia, hypoglycemia), anemia, and gastrointestinal symptoms (abdominal distension and hepatomegaly) completed the clinical presentation.[<xref ref-type="bibr" rid="ref11">11</xref>] The initial paradigm of the exclusive PLP responsiveness of PNPO deficiency has been recently denied with the demonstration of a clinical or electroencephalographic response to pyridoxine in 12 patients (two of them suffered from status epilepticus after the switch from pyridoxine to PLP).[<xref ref-type="bibr" rid="ref11">11</xref><xref ref-type="bibr" rid="ref12">12</xref>] The best diagnostic issue for PNPO deficiency remains PNPO gene sequencing in children with a response to a therapeutic trial of PLP or pyridoxine.[<xref ref-type="bibr" rid="ref11">11</xref>]</p>
<p>All children with PNPO deficiency should undergo sequential trials with PLP or, in case of unresponsiveness, pyridoxine.[<xref ref-type="bibr" rid="ref11">11</xref><xref ref-type="bibr" rid="ref12">12</xref>]</p>
<p>PLP can be administered orally or enterally at 30–60 mg/kg/day, even if some patients required higher dosages up to 100 mg/kg/day.[<xref ref-type="bibr" rid="ref13">13</xref>] Pyridoxine can be administered as in <italic>ALDH7A1</italic> deficiency.[<xref ref-type="bibr" rid="ref11">11</xref><xref ref-type="bibr" rid="ref12">12</xref><xref ref-type="bibr" rid="ref13">13</xref><xref ref-type="bibr" rid="ref14">14</xref><xref ref-type="bibr" rid="ref15">15</xref><xref ref-type="bibr" rid="ref16">16</xref><xref ref-type="bibr" rid="ref17">17</xref>]</p>
</sec>
<sec id="sec2-3">
<title>Hyperprolinemia type II</title>
<p>Hyperprolinemia type II is a rare autosomal-recessive disorder that is caused by mutations in <italic>ALDH4A1</italic> gene resulting in a deficiency of Δ-1-pyrroline-5-carboxylate dehydrogenase, a mitochondrial inner-membrane enzyme involved in the conversion of proline to glutamate [<xref ref-type="fig" rid="F2">Figure 2</xref>]. This defect results in pyridoxine depletion and in subsequent seizures.[<xref ref-type="bibr" rid="ref18">18</xref>]</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Metabolism of proline. Double black labels indicate the defect of Δ-1-pyrroline-5-carboxylate dehydrogenase in hyperprolinemia type II. The enzyme defect results in an accumulation of proline and Δ-1-pyrroline-5-carboxylate. Δ-1-pyrroline-5-carboxylate induces inactivating adduct with pyridoxine with subsequent possible seizures resulting from pyridoxine depletion</p>
</caption>
<graphic xlink:href="JPN-13-13-g002"></graphic>
</fig>
<p>Hyperprolinemia type II is a benign disorder with a high predisposition to recurrent seizures.[<xref ref-type="bibr" rid="ref19">19</xref>] Seizures responsive to trials with intravenous pyridoxine without evidences of <italic>ALDH7A1</italic> or PNPO deficiency should suggest the diagnostic suspect of this disorder.[<xref ref-type="bibr" rid="ref19">19</xref>] Biochemical markers include increased plasma proline, increased urinary Δ-1-pyrroline-5-carboxylate, and reduced Δ-1-pyrroline-5-carboxylate dehydrogenase activity in leukocytes and skin fibroblast.[<xref ref-type="bibr" rid="ref19">19</xref>]</p>
<p>Seizures are commonly controlled with pyridoxine supplementation.[<xref ref-type="bibr" rid="ref19">19</xref>] No specific dietary treatments are indicated.[<xref ref-type="bibr" rid="ref19">19</xref>]</p>
</sec>
</sec>
<sec id="sec1-3">
<title>C<sc>EREBRAL</sc> F<sc>OLATE</sc> D<sc>EFICIENCY</sc></title>
<p>Cerebral folate deficiency (OMIM 613068) causing folinic-responsive epilepsy includes two disorders resulting from dysfunctions of cerebral folate receptor FOLR1: mutation of the FOLR1 encoding gene with an autosomal-recessive transmission or production of FOLR1 blocking/binding autoantibodies.[<xref ref-type="bibr" rid="ref20">20</xref>]</p>
<p>Cerebral folate deficiency presents as an encephalopathy including psychomotor retardation after an initial period of normal neuromotor development, autistic-like behavior or behavioral abnormalities, decelerated head growth, ataxia, hypotonia, spasticity, dyskinesia, and early-onset epilepsy with onset within the third year of life.[<xref ref-type="bibr" rid="ref20">20</xref>] Myoclonic seizures are the most common seizure type even though tonic and astatic seizures and episodes resembling infantile spasms have also been reported.[<xref ref-type="bibr" rid="ref21">21</xref>]</p>
<p>The main biochemical marker of a cerebral folate deficiency is represented by an extremely low 5-methyltetrahydrofolate concentration in the cerebrospinal fluid without evidences of peripheral folate depletion.[<xref ref-type="bibr" rid="ref20">20</xref><xref ref-type="bibr" rid="ref21">21</xref>] If this abnormal value is detected, then FOLR1 gene sequencing and plasma FOLR1 blocking or binding autoantibodies measurement should be taken into account in the diagnostic workup.[<xref ref-type="bibr" rid="ref20">20</xref><xref ref-type="bibr" rid="ref21">21</xref>]</p>
<p>Neuroradiological patterns in patients with cerebral folate deficiency include delayed myelination, cerebellar atrophy, bilateral calcifications in the basal ganglia, and decreased choline and inositol peaks on magnetic resonance spectroscopy.[<xref ref-type="bibr" rid="ref20">20</xref><xref ref-type="bibr" rid="ref21">21</xref>]</p>
<p>Seizures respond to oral supplementation of folinic acid (1–5 mg/kg/day) with a subsequent possible improvement in the whole clinical outcome, whereas folic acid is found to be ineffective (in some cases, a worsening of seizures has been reported).[<xref ref-type="bibr" rid="ref20">20</xref><xref ref-type="bibr" rid="ref21">21</xref><xref ref-type="bibr" rid="ref22">22</xref>] A possible therapeutic role of milk-free diet has been advocated for cerebral folate deficiency due to FOLR1 blocking or binding autoantibodies.[<xref ref-type="bibr" rid="ref22">22</xref>] The rational basis for this approach has been provided by recent studies that demonstrated a downregulation in the production of FOLR1 autoantibodies.[<xref ref-type="bibr" rid="ref23">23</xref>]</p>
</sec>
<sec id="sec1-4">
<title>C<sc>ONGENITAL</sc> D<sc>ISORDERS OF</sc> S<sc>ERINE</sc> M<sc>ETABOLISM</sc></title>
<p>Four clinically defined congenital disorders, with overlapping clinical features, of serine metabolism [<xref ref-type="fig" rid="F3">Figure 3</xref>] have been reported: 3-phosphoglycerate dehydrogenase (3-PGDH; OMIM 601815), phosphoserine aminotransferase (PSAT; OMIM 610992), phosphoserine phosphatase (PSP; OMIM 172480), and serine transporter (OMIM 616657) deficiency.[<xref ref-type="bibr" rid="ref23">23</xref><xref ref-type="bibr" rid="ref24">24</xref>] 3-PGDH deficiency is transmitted as an autosomal-recessive disorder.[<xref ref-type="bibr" rid="ref23">23</xref>] A compound heterozygous mutation in PSAT1 gene has been demonstrated in two index siblings with PSAT deficiency.[<xref ref-type="bibr" rid="ref23">23</xref>] PSP deficiency is inherited through an autosomal-recessive transmission.[<xref ref-type="bibr" rid="ref23">23</xref>] Serine transporter deficiency is caused by autosomal-recessive disorders following mutations in SLC1A4 gene and includes a phenotype with developmental delay, progressive microcephaly, hypomyelination, and seizures.[<xref ref-type="bibr" rid="ref24">24</xref>]</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>Schematic representation of serine metabolism</p>
</caption>
<graphic xlink:href="JPN-13-13-g003"></graphic>
</fig>
<p>3-PGDH deficiency is the most common congenital disorder of serine metabolism and includes an infantile, a juvenile, and an adult phenotype.[<xref ref-type="bibr" rid="ref23">23</xref>] Infantile presentation includes congenital microcephaly, intrauterine growth retardation, intractable seizures, severe psychomotor retardation, spastic quadriplegia, congenital cataract, hypogonadism, and megaloblastic anemia.[<xref ref-type="bibr" rid="ref23">23</xref>] Seizure types include infantile spasms (75% of the affected patients), tonic–clonic seizures, tonic seizures, atonic seizures, absence seizures, gelastic seizures, and myoclonic seizures.[<xref ref-type="bibr" rid="ref23">23</xref>] After adolescence, the clinical pattern is characterized by mild or moderate intellectual deficiency, absence seizures, and behavioral problems.[<xref ref-type="bibr" rid="ref23">23</xref>] In adulthood, intellectual disability, peripheral polyneuropathy, cerebellar ataxia, and nystagmus have been described.[<xref ref-type="bibr" rid="ref23">23</xref>]</p>
<p>PSAT deficiency usually presents with acquired microcephaly, feeding difficulties, and intractable seizures.[<xref ref-type="bibr" rid="ref23">23</xref><xref ref-type="bibr" rid="ref25">25</xref>] PSP deficiency has been reported in a single patient with Williams syndrome presenting with Intrauterine Growth Retardation (IUGR), congenital microcephaly, slow psychomotor development, and feeding difficulties.[<xref ref-type="bibr" rid="ref23">23</xref><xref ref-type="bibr" rid="ref26">26</xref>]</p>
<p>The main biochemical marker of congenital disorders of serine metabolism is represented by low levels of serine in cerebrospinal fluid (under 13 μmol/L in 3-PGDH deficiency and up to 18 μmol/L in PSAT and PSP deficiency) and in plasma (the sample must be obtained in fasted state).[<xref ref-type="bibr" rid="ref23">23</xref><xref ref-type="bibr" rid="ref26">26</xref><xref ref-type="bibr" rid="ref27">27</xref>] Low levels of glycine can also be observed.[<xref ref-type="bibr" rid="ref23">23</xref>] Enzyme activity in skin fibroblast can be useful in the workup for 3-PGDH and PSP deficiency, whereas it was inconclusive in the index patient with PSAT deficiency.[<xref ref-type="bibr" rid="ref23">23</xref><xref ref-type="bibr" rid="ref26">26</xref><xref ref-type="bibr" rid="ref27">27</xref>] Molecular genetic confirmation is required for all the three abovementioned disorders.[<xref ref-type="bibr" rid="ref23">23</xref><xref ref-type="bibr" rid="ref26">26</xref><xref ref-type="bibr" rid="ref27">27</xref>]</p>
<p>Brain neuroimaging evidences hypomyelination or delayed myelination in 3-PGDH deficiency and cortical/subcortical atrophy associated with diffused white matter abnormalities in PSAT deficiency.[<xref ref-type="bibr" rid="ref23">23</xref><xref ref-type="bibr" rid="ref26">26</xref>]</p>
<p>In infantile phenotype of 3-PGDH deficiency, an oral supplementation of serine (dosage range, 200–700 mg/kg/day) resulted in seizure control, normalization of serine levels in cerebrospinal fluid, and in the progression of head growth in most of the reported patients.[<xref ref-type="bibr" rid="ref23">23</xref>] A further supplementation of glycine (200 mg/kg/day) was often required to stabilize the clinical improvements.[<xref ref-type="bibr" rid="ref23">23</xref>] Similar results, with lower dosages of serine (100–150 mg/kg/day), were obtained in subjects with the juvenile phenotype.[<xref ref-type="bibr" rid="ref23">23</xref>] In the adult phenotype, an improvement in the daily activities was reported with the dosage of serine up to 80–120 mg/kg/day.[<xref ref-type="bibr" rid="ref23">23</xref>] Complete prevention of neurological manifestations has been obtained in a patient, whose mother received an oral supplementation of serine since the 27th week of gestation after a prenatal diagnosis of 3-PGDH, and in a female who was treated after a diagnosis of PSAT deficiency in the first day of life.[<xref ref-type="bibr" rid="ref23">23</xref>] No clinical trials were performed for serine transporter deficiency.[<xref ref-type="bibr" rid="ref24">24</xref>]</p>
</sec>
<sec id="sec1-5">
<title>B<sc>IOTINIDASE</sc> D<sc>EFICIENCY</sc></title>
<p>Biotinidase deficiency (OMIM 253260) is a congenital disorder with an autosomal-recessive inheritance resulting in an absence of recycling of biotin with subsequent impairments of the main biotin-dependent carboxylases [<xref ref-type="fig" rid="F4">Figure 4</xref>] and accumulation of potentially neurotoxic and epileptogenic metabolites.[<xref ref-type="bibr" rid="ref27">27</xref>]</p>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p>Schematic representation of biotin cycle</p>
</caption>
<graphic xlink:href="JPN-13-13-g004"></graphic>
</fig>
<p>Patients with biotinidase deficiency present with seizures, hypotonia, nutritional or respiratory problems, skin rash, and alopecia.[<xref ref-type="bibr" rid="ref28">28</xref>] Seizure semiology is variable as well as electroencephalographic patterns (ranging from normality to hypsarrhythmia).[<xref ref-type="bibr" rid="ref28">28</xref>] In the later ages, developmental delay, ataxia, optic neuropathy, and hearing loss are very frequent.[<xref ref-type="bibr" rid="ref29">29</xref>] Brain neuroimaging demonstrates normal findings or variable structural abnormalities such as cortical/subcortical atrophy, decreased white matter, ventricular enlargement, and abnormal signal in the basal ganglia (decrease or swelling of all the basal ganglia, hypointensity of the lentiform nuclei and caudate, or hyperintensity in the globus pallidus).[<xref ref-type="bibr" rid="ref28">28</xref>]</p>
<p>Biochemical markers of biotinidase deficiency include more- (increase in urinary organic acid, especially 3-hydroxyisovalerate, resulting from biotin-dependent carboxylase dysfunction) or less-specific abnormalities (lactic acidosis and moderate hyperammonemia).[<xref ref-type="bibr" rid="ref28">28</xref>] An assay to detect biotinidase enzyme activity on dried blood spot is available.[<xref ref-type="bibr" rid="ref29">29</xref>] Molecular genetic analysis is useful for the diagnostic confirmation, especially in the partial enzyme deficiency.[<xref ref-type="bibr" rid="ref28">28</xref><xref ref-type="bibr" rid="ref29">29</xref>]</p>
<p>Seizures are promptly responsive to oral supplementation of biotin (5–10 mg/day).[<xref ref-type="bibr" rid="ref28">28</xref><xref ref-type="bibr" rid="ref29">29</xref>] In this context, a trial with oral biotin is strongly recommended for diagnostic and therapeutic purposes in all early-onset drug-resistant seizures, if clinical phenotype is compatible.[<xref ref-type="bibr" rid="ref28">28</xref><xref ref-type="bibr" rid="ref29">29</xref>] The administration of oral biotin in presymptomatic children, who are diagnosed early through specific newborn-screening programs, can prevent all clinical and biochemical abnormalities.[<xref ref-type="bibr" rid="ref28">28</xref><xref ref-type="bibr" rid="ref29">29</xref>] Recommended dosage varies from 1–5 to 2.5–10 mg/day according to the severity of the enzyme activity deficiency.[<xref ref-type="bibr" rid="ref28">28</xref><xref ref-type="bibr" rid="ref29">29</xref>]</p>
</sec>
<sec id="sec1-6">
<title>I<sc>NBORN</sc> E<sc>RRORS OF</sc> C<sc>REATINE</sc> M<sc>ETABOLISM</sc></title>
<p>Creatine metabolism [<xref ref-type="fig" rid="F5">Figure 5</xref>] disorders include three rare diseases in which the intracellular transfer of energy, especially in muscle and brain, is impaired: guanidinoacetate methyltransferase (GAMT; OMIM 601240), arginine:glycine amidinotransferase (AGAT; OMIM 602360), and creatine transporter 1 (CT1; OMIM 300036) deficiency.[<xref ref-type="bibr" rid="ref29">29</xref>] GAMT and AGAT deficiency are autosomal-recessive disorders, whereas CT1 deficiency is transmitted through an X-linked mechanism.[<xref ref-type="bibr" rid="ref30">30</xref>]</p>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<p>Schematic representation of creatine metabolism</p>
</caption>
<graphic xlink:href="JPN-13-13-g005"></graphic>
</fig>
<p>Clinical symptoms result from a decrease in cerebral creatine (in all the three disorders) and from the toxic effects of accumulated metabolites (guanidinoacetate in GAMT deficiency).[<xref ref-type="bibr" rid="ref30">30</xref>]</p>
<p>GAMT, AGAT, and CT1 deficiency share a cluster of common symptoms including intellectual disability, language delay, and behavioral disorders.[<xref ref-type="bibr" rid="ref30">30</xref>] Epileptic seizures (including myoclonic seizures, myoclonic astatic seizures, generalized tonic–clonic seizures, partial seizures with secondary generalization, drop attacks, and absences) are often the initial symptoms in GAMT deficiency.[<xref ref-type="bibr" rid="ref30">30</xref>] GAMT deficiency results in a severe early-onset epileptic encephalopathy, developmental delay or neurological deterioration, intellectual disability, autistic-like behavior, and movement disorders (such as athetosis, chorea, choreoathetosis, ballism, and dystonia).[<xref ref-type="bibr" rid="ref30">30</xref>]</p>
<p>In AGAT deficiency, seizures are uncommon (apart from febrile seizures).[<xref ref-type="bibr" rid="ref30">30</xref>] In CT1 deficiency, epilepsy is drug responsive and less severe than in GAMT deficiency.[<xref ref-type="bibr" rid="ref30">30</xref>]</p>
<p>None of the inborn errors of creatine metabolism has typical electroencephalographic patterns.[<xref ref-type="bibr" rid="ref30">30</xref>] MRI of the brain demonstrates bilateral pallidal lesions in GAMT deficiency and a lack of creatine peak in the spectroscopy for all the three abovementioned disorders.[<xref ref-type="bibr" rid="ref30">30</xref>]</p>
<p>Increased levels of guanidinoacetate in all body fluids (mainly cerebrospinal fluid and blood) are the main biochemical marker of GAMT deficiency.[<xref ref-type="bibr" rid="ref30">30</xref>] Low levels of guanidinoacetate in plasma, urine, and cerebrospinal fluid can be observed in AGAT deficiency.[<xref ref-type="bibr" rid="ref30">30</xref>] An increased urinary creatine/creatinine ratio is typical in CT1 deficiency.[<xref ref-type="bibr" rid="ref30">30</xref>] Specifically oriented gene sequencing for GAMT, AGAT, or CT1 deficiency should always be performed, if these biochemical abnormalities are recorded.[<xref ref-type="bibr" rid="ref30">30</xref>]</p>
<p>In GAMT deficiency, an oral supplementation of creatine monohydrate (0.350–2g/kg/day) results in the control of seizures and movement disorders, the regression of bilateral pallidal lesions, and in the restoration of creatine pools in the muscle (increased plasma creatine levels) and in the brain (reappearance of creatine peak in the magnetic resonance spectroscopy).[<xref ref-type="bibr" rid="ref30">30</xref>] Additional dietary restriction of arginine (15 mg/kg/day) and supplementation of ornithine aspartate (350–800 mg/kg/day) provide further benefits for long-term outcome.[<xref ref-type="bibr" rid="ref30">30</xref>] These treatments have generally no effects on neurocognitive, neuromotor, and behavioral development.[<xref ref-type="bibr" rid="ref30">30</xref>]</p>
<p>In AGAT deficiency, creatine oral supplementation improves clinical outcome, whereas no effective treatment exists for CT1 deficiency.[<xref ref-type="bibr" rid="ref30">30</xref>]</p>
</sec>
<sec id="sec1-7">
<title>M<sc>OLYBDENUM</sc> C<sc>OFACTOR</sc> D<sc>EFICIENCY</sc></title>
<p>Molybdenum cofactor deficiency (OMIM 252150) is an autosomal-recessive disorder resulting in the impairment of molybdenum-dependent enzymes including sulfite oxidase, xanthine oxidase, nitrate reductase, and nitrogenases.[<xref ref-type="bibr" rid="ref31">31</xref>] More than 30 disease-causing mutations in genes encoding for the enzymes involved in the biosynthesis of molybdenum cofactor [<xref ref-type="fig" rid="F6">Figure 6</xref>] have been reported in the literature.[<xref ref-type="bibr" rid="ref31">31</xref>] Two-third of the patients with molybdenum cofactor deficiency are classified as having molybdenum cofactor type A deficiency (lack of cyclic pyranopterin monophosphate [cPMP] [<xref ref-type="fig" rid="F6">Figure 6</xref>]).[<xref ref-type="bibr" rid="ref31">31</xref>]</p>
<fig id="F6" position="float">
<label>Figure 6</label>
<caption>
<p>Biosynthesis of molybdenum cofactor and metabolic steps regulated by molybdenum cofactor</p>
</caption>
<graphic xlink:href="JPN-13-13-g006"></graphic>
</fig>
<p>The neurotoxic effects of accumulated sulfites resulting from the deficient activity of sulfite oxidase have been suggested as the main pathogenic mechanism for brain damage.[<xref ref-type="bibr" rid="ref31">31</xref>]</p>
<p>Two phenotypes of molybdenum cofactor deficiency were reported in the literature: an early presentation with a severe epileptic encephalopathy (intractable neonatal seizures, tonus abnormalities, respiratory distress, and feeding difficulties) and an atypical later pattern with a global developmental delay.[<xref ref-type="bibr" rid="ref30">30</xref>] Language, visual, and motor impairment with different degree of severity were present in all the reported patients.[<xref ref-type="bibr" rid="ref31">31</xref>] Puffy cheeks and a small nose with a long philtrum represented distinctive facial features in some patients.[<xref ref-type="bibr" rid="ref32">32</xref>]</p>
<p>Suppression burst pattern is often present in the electroencephalogram even if no pathognomonic traces have been characterized.[<xref ref-type="bibr" rid="ref32">32</xref>]</p>
<p>Brain MRI pattern includes symmetrical pallidal or subthalamic lesions, areas of cerebral infarction, subcortical multicystic lesions, progressive cortical and subcortical atrophy, and diffused white matter abnormalities.[<xref ref-type="bibr" rid="ref31">31</xref>] Laboratory investigations in molybdenum cofactor deficiency evidence a decrease in serum and urinary uric acid, a positive urinary sulfite test, and an elevated urinary xanthine, hypoxanthine, and <italic>S</italic>-sulfocysteine.[<xref ref-type="bibr" rid="ref31">31</xref><xref ref-type="bibr" rid="ref32">32</xref>]</p>
<p>One patient with molybdenum cofactor deficiency type A was treated with intravenous purified cPMP at a dosage of 80–160 μg/kg/day.[<xref ref-type="bibr" rid="ref32">32</xref>] The treatment resulted in a remarkable clinical and electroencephalographic improvement (including seizure control, improvement of alertness and twitching disappearance, reappearance of rhythmic elements, and reduction of epileptiform discharges) and in the normalization of the biochemical markers.[<xref ref-type="bibr" rid="ref33">33</xref>] A patient with a prenatally diagnosed molybdenum cofactor deficiency type A, treated with cPMP 80 μg/kg at 4h after birth and up to 240 μg/kg at 100 days of life, was also described.[<xref ref-type="bibr" rid="ref30">30</xref>] The patient did not experience seizures after the first day of life with the normalization of urinary sulfite, <italic>S</italic>-sulfocysteine, xanthine, and uric acid within 1–2 weeks.[<xref ref-type="bibr" rid="ref30">30</xref>] At the age of 21 months, a mild cognitive delay without motor deficits was observed.[<xref ref-type="bibr" rid="ref30">30</xref>] Comparable benefits were observed in 8 of the 11 patients with molybdenum cofactor deficiency type A, who became seizure-free with normal levels of urine <italic>S</italic>-sulfocysteine, xanthine, and urate after 5 years of treatment.[<xref ref-type="bibr" rid="ref30">30</xref>]</p>
</sec>
<sec id="sec1-8">
<title>GLUT1 D<sc>EFICIENCY</sc></title>
<p>Glucose transporter 1 (GLUT1) is a facilitative glucose transporter with a prominent expression in brain, placenta, and erythrocytes.[<xref ref-type="bibr" rid="ref34">34</xref>] GLUT1 deficiency syndrome (OMIM 138140) is generally due to de novo SCL2A1 mutations or, in familial cases, due to mutations that are transmitted through an autosomal dominant mechanism.[<xref ref-type="bibr" rid="ref34">34</xref>]</p>
<p>GLUT1 deficiency syndrome includes a classical phenotype (early-onset epileptic encephalopathy, acquired microcephaly, developmental delay, hypotonia, spasticity, and movement disorders including dystonia and ataxia) and various nonclassical phenotypes (early-onset absences, paroxysmal exercise-induced dystonia with or without seizures, choreoathetosis, alternating hemiplegia, intermittent ataxia, language delay, expressive language difficulties, learning difficulties, different degree of cognitive delay, and migraine).[<xref ref-type="bibr" rid="ref33">33</xref>]</p>
<p>Electroencephalogram can show various epileptic abnormalities.[<xref ref-type="bibr" rid="ref34">34</xref>] It has reported a typical reduction of some abnormalities, such as slow waves, after a meal.[<xref ref-type="bibr" rid="ref34">34</xref>] Magnetic resonance is usually nondiagnostic.[<xref ref-type="bibr" rid="ref33">33</xref>] Positron-emission tomography often demonstrates a decrease in cortical (prominently in the mesial temporal regions) and thalamic glucose uptake.[<xref ref-type="bibr" rid="ref34">34</xref>]</p>
<p>The main biochemical hallmark for GLUT1 deficiency syndrome is hypoglycorrhachia.[<xref ref-type="bibr" rid="ref34">34</xref>] Cerebrospinal fluid-to-blood glucose ratio level lower than 0.35 is considered as strongly suggestive of GLUT1 deficiency (even if in milder phenotype, the ratio can be higher than 0.59).[<xref ref-type="bibr" rid="ref34">34</xref>] Clinicians should take into account that hypoglycorrachia can be also observed in meningitis, status epilepticus, mitochondrial diseases, hypoglycemic states, subarachnoid hemorrhage, and meningeal carcinomatosis.[<xref ref-type="bibr" rid="ref34">34</xref>] These disorders should be carefully excluded before performing second-level investigations for GLUT1 deficiency (test for uptake of 3-<italic>O</italic>-methylglucose into erythrocytes and SLC2A1 gene sequencing).[<xref ref-type="bibr" rid="ref34">34</xref>] The normal values of cells, proteins, and lactate, which are observed in GLUT1 deficiency, are useful in differential diagnosis of infectious, inflammatory, and mitochondrial diseases.[<xref ref-type="bibr" rid="ref34">34</xref>]</p>
<p>Ketogenic diet remains to be the gold standard for treatment of GLUT1 deficiency because it represents an alternative source of energy for the brain.[<xref ref-type="bibr" rid="ref34">34</xref>] It includes high proportion of fats and a restriction of carbohydrates and it mimics the metabolic state of fasting with an increased production of ketones.[<xref ref-type="bibr" rid="ref34">34</xref>]</p>
<p>Ketogenic diet in patients with GLUT1 deficiency induces an optimal seizure control and it also results in a decrease in movement disorders (especially dystonia, paroxysmal exercise-induced dyskinesia, and ataxia).[<xref ref-type="bibr" rid="ref34">34</xref>] The evaluation of its effects on the cognitive outcome requires further studies.[<xref ref-type="bibr" rid="ref34">34</xref>]</p>
<p>Alternative promising treatments for GLUT1 deficiency in the future will be represented by alpha-lipoic acid (an antioxidant that improves cellular glucose uptake and transport) and triheptanoin (a triglyceride that strengthens the function of common ketones).[<xref ref-type="bibr" rid="ref34">34</xref>]</p>
</sec>
<sec id="sec1-9">
<title>C<sc>ONCLUDING</sc> R<sc>EMARKS</sc></title>
<p>The expanding group of treatable metabolic epilepsy also includes Mabry syndrome (treatable with pyridoxine), milder forms of nonketotic hyperglycinemia (treatable with dextromethorphan and benzoate therapy), pyruvate dehydrogenase deficiency (that can be responsive to ketogenic diet and thiamine), congenital neurotransmitter deficiencies (pyruvate carboxylase deficiency can be responsive to tetrahydrobiopterin), holocarboxylase synthetase deficiency (treatable with biotin), and succinic semialdehyde dehydrogenase deficiency (that can be responsive to vigabatrin).[<xref ref-type="bibr" rid="ref2">2</xref>] A detailed discussion of their features is beyond the scope of this review.</p>
<p>New next-generation sequencing techniques explore hundreds of genes in single experiment with relevant gains in the most clinically ambiguous cases.[<xref ref-type="bibr" rid="ref35">35</xref>] Despite these progresses, the diagnostic approach for treatable inborn errors of metabolism causing epilepsy should always be based on clinical evaluation and on the subsequent interpretation of a restricted group of biochemical markers in selected subjects [see <xref ref-type="table" rid="T1">Table 1</xref>].[<xref ref-type="bibr" rid="ref1">1</xref>]</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Proposed checklist for metabolic workup in epileptic children</p>
</caption>
<graphic xlink:href="JPN-13-13-g007"></graphic>
</table-wrap>
<sec id="sec2-4">
<title>Financial support and sponsorship</title>
<p>Nil.</p>
</sec>
<sec id="sec2-5" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>There are no conflicts of interest.</p>
</sec>
</sec>
</body>
<back>
<ref-list>
<title>R<sc>EFERENCES</sc></title>
<ref id="ref1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mastrangelo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Celato</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Leuzzi</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>A diagnostic algorithm for the evaluation of early onset genetic metabolic epileptic encephalopathies</article-title>
<source/>Eur J Paediatr Neurol
          <year>2012</year>
<volume>16</volume>
<fpage>179</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="pmid">21940184</pub-id>
</element-citation>
</ref>
<ref id="ref2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dulac</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Plecko</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gataullina</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>NI</given-names>
</name>
</person-group>
<article-title>Occasional seizures, epilepsy, and inborn errors of metabolism</article-title>
<source/>Lancet Neurol
          <year>2014</year>
<volume>13</volume>
<fpage>727</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="pmid">24943345</pub-id>
</element-citation>
</ref>
<ref id="ref3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mills</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Struys</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Jakobs</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Plecko</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Baxter</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Baumgartner</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in antiquitin in individuals with pyridoxine-dependent seizures</article-title>
<source/>Nat Med
          <year>2006</year>
<volume>12</volume>
<fpage>307</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">16491085</pub-id>
</element-citation>
</ref>
<ref id="ref4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mills</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Footitt</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Mills</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Tuschl</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Aylett</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Varadkar</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency)</article-title>
<source/>Brain
          <year>2010</year>
<volume>133</volume>
<fpage>2148</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="pmid">20554659</pub-id>
</element-citation>
</ref>
<ref id="ref5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bok</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Maurits</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Willemsen</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Jakobs</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Teune</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Poll-The</surname>
<given-names>BT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The EEG response to pyridoxine-IV neither identifies nor excludes pyridoxine-dependent epilepsy</article-title>
<source/>Epilepsia
          <year>2010</year>
<volume>51</volume>
<fpage>1</fpage>
</element-citation>
</ref>
<ref id="ref6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Karnebeek</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Stockler-Ipsiroglu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jaggumantri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Assmann</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Baxter</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Buhas</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lysine-restricted diet as adjunct therapy for pyridoxine-dependent epilepsy: The PDE Consortium Consensus Recommendations</article-title>
<source/>JIMD Rep
          <year>2014</year>
<volume>15</volume>
<fpage>1</fpage>
<lpage>11</lpage>
</element-citation>
</ref>
<ref id="ref7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pérez</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gutiérrez-Solana</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Verdú</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Merinero</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Yuste-Checa</surname>
<given-names>P</given-names>
</name>
<name>
<surname>RuizSala</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical, biochemical, and molecular studies in pyridoxine-dependent epilepsy. Antisense therapy as possible new therapeutic option</article-title>
<source/>Epilepsia
          <year>2013</year>
<volume>54</volume>
<fpage>239</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">23350806</pub-id>
</element-citation>
</ref>
<ref id="ref8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mercimek-Mahmutoglu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cordeiro</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cruz</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Hyland</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Struys</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Kyriakopoulou</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Novel therapy for pyridoxine dependent epilepsy due to <italic>ALDH7A1</italic> genetic defect: L-arginine supplementation alternative to lysine-restricted diet</article-title>
<source/>Eur J Paediatr Neurol
          <year>2014</year>
<volume>18</volume>
<fpage>741</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">25127453</pub-id>
</element-citation>
</ref>
<ref id="ref9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gallagher</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Van Hove</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Scharer</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hyland</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Plecko</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Waters</surname>
<given-names>PJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Folinic acid–responsive seizures are identical to pyridoxine-dependent epilepsy</article-title>
<source/>Ann Neurol
          <year>2009</year>
<volume>65</volume>
<fpage>550</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">19142996</pub-id>
</element-citation>
</ref>
<ref id="ref10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mills</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Camuzeaux</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Footitt</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Mills</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Gissen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epilepsy due to PNPO mutations: Genotype, environment and treatment affect presentation and outcome</article-title>
<source/>Brain
          <year>2014</year>
<volume>137</volume>
<fpage>1350</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">24645144</pub-id>
</element-citation>
</ref>
<ref id="ref11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mills</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Surtees</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Champion</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Beesley</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Dalton</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Scambler</surname>
<given-names>PJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5-primephosphate oxidase</article-title>
<source/>Hum Mol Genet
          <year>2005</year>
<volume>14</volume>
<fpage>1</fpage>
<pub-id pub-id-type="pmid">15525660</pub-id>
</element-citation>
</ref>
<ref id="ref12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plecko</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mills</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Clayton</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Paschke</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Maier</surname>
<given-names>O</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pyridoxine responsiveness in novel mutations of the PNPO gene</article-title>
<source/>Neurology
          <year>2014</year>
<volume>22</volume>
<fpage>1425</fpage>
<lpage>33</lpage>
</element-citation>
</ref>
<ref id="ref13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guerin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Aziz</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Mutch</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Go</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Mercimek-Mahmutoglu</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Pyridox(am)ine-5-phosphate oxidase deficiency treatable cause of neonatal epileptic encephalopathy with burst suppression: Case report and review of the literature</article-title>
<source/>J Child Neurol
          <year>2015</year>
<volume>30</volume>
<fpage>1218</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="pmid">25296925</pub-id>
</element-citation>
</ref>
<ref id="ref14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pearl</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Gospe</surname>
<given-names>SM</given-names>
<suffix>Jr</suffix>
</name>
</person-group>
<article-title>Pyridoxine or pyridoxal-5′-phosphate for neonatal epilepsy: The distinction just got murkier</article-title>
<source/>Neurology
          <year>2014</year>
<volume>82</volume>
<fpage>1392</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="pmid">24658927</pub-id>
</element-citation>
</ref>
<ref id="ref15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sudarsanam</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wilcken</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Stormon</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Arbuckle</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cirrhosis associated with pyridoxal 5′-phosphate treatment of pyridoxamine 5′-phosphate oxidase deficiency</article-title>
<source/>JIMD Rep
          <year>2014</year>
<volume>17</volume>
<fpage>67</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="pmid">25256445</pub-id>
</element-citation>
</ref>
<ref id="ref16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pearl</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Hyland</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chiles</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McGavin</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Partial pyridoxine responsiveness in PNPO deficiency</article-title>
<source/>JIMD Rep
          <year>2013</year>
<volume>9</volume>
<fpage>139</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="pmid">23430561</pub-id>
</element-citation>
</ref>
<ref id="ref17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaeger</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Abeling</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Salomons</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Struys</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Simas-Mendes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Geukers</surname>
<given-names>VG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pyridoxine responsive epilepsy caused by a novel homozygous PNPO mutation</article-title>
<source/>Mol Genet Metab Rep
          <year>2016</year>
<volume>6</volume>
<fpage>60</fpage>
<lpage>3</lpage>
<pub-id pub-id-type="pmid">27014579</pub-id>
</element-citation>
</ref>
<ref id="ref18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farrant</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Mills</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Mellor</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Langley</surname>
<given-names>GJ</given-names>
</name>
</person-group>
<article-title>Pyridoxal phosphate deactivation by pyrroline-5-carboxylic acid. Increased risk of vitamin B6 deficiency and seizures in hyperprolinemia type II</article-title>
<source/>J Biol Chem
          <year>2000</year>
<volume>276</volume>
<fpage>15107</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="pmid">11134058</pub-id>
</element-citation>
</ref>
<ref id="ref19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitsubuchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Endo</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Biochemical and clinical features of hereditary hyperprolinemia</article-title>
<source/>Pediatr Int
          <year>2014</year>
<volume>56</volume>
<fpage>492</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">24931297</pub-id>
</element-citation>
</ref>
<ref id="ref20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grapp</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Just</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Linnankivi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lücke</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Häusler</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Molecular characterization of folate receptor 1 mutations delineates cerebral folate transport deficiency</article-title>
<source/>Brain
          <year>2012</year>
<volume>133</volume>
<fpage>2022</fpage>
<lpage>31</lpage>
</element-citation>
</ref>
<ref id="ref21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steele</surname>
<given-names>SU</given-names>
</name>
<name>
<surname>Cheah</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Veerapandiyan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gallentine</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Mikati</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Electroencephalographic and seizure manifestations in two patients with folate receptor autoimmune antibody-mediated primary cerebral folate deficiency</article-title>
<source/>Epilepsy Behav
          <year>2012</year>
<volume>24</volume>
<fpage>507</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="pmid">22749608</pub-id>
</element-citation>
</ref>
<ref id="ref22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramaekers</surname>
<given-names>VT</given-names>
</name>
<name>
<surname>Sequeira</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Blau</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Quadros</surname>
<given-names>EV</given-names>
</name>
</person-group>
<article-title>A milk-free diet downregulates folate receptor autoimmunity in cerebral folate deficiency syndrome</article-title>
<source/>Dev Med Child Neurol
          <year>2008</year>
<volume>50</volume>
<fpage>346</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">18355335</pub-id>
</element-citation>
</ref>
<ref id="ref23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Crabben</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Verhoeven-Duif</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Brilstra</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Van Maldergem</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Coskun</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rubio-Gozalbo</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>An update on serine deficiency disorders</article-title>
<source/>J Inherit Metab Dis
          <year>2013</year>
<volume>36</volume>
<fpage>613</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">23463425</pub-id>
</element-citation>
</ref>
<ref id="ref24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Damseh</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Simonin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jalas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Picoraro</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Shaag</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>MT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in SLC1A4, encoding the brain serine transporter, are associated with developmental delay, microcephaly and hypomyelination</article-title>
<source/>J Med Genet
          <year>2015</year>
<volume>52</volume>
<fpage>541</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">26041762</pub-id>
</element-citation>
</ref>
<ref id="ref25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hart</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Race</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Achouri</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wiame</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sharrard</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Olpin</surname>
<given-names>SE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phosphoserine aminotransferase deficiency: A novel disorder of the serine biosynthesis pathway</article-title>
<source/>Am J Hum Genet
          <year>2007</year>
<volume>80</volume>
<fpage>931</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">17436247</pub-id>
</element-citation>
</ref>
<ref id="ref26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaeken</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Detheux</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fryns</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Collet</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Alliet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Van Schaftingen</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Phosphoserine phosphatase deficiency in a patient with Williams syndrome</article-title>
<source/>J Med Genet
          <year>1997</year>
<volume>34</volume>
<fpage>594</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">9222972</pub-id>
</element-citation>
</ref>
<ref id="ref27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolf</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>The neurology of biotinidase deficiency</article-title>
<source/>Mol Genet Metab
          <year>2011</year>
<volume>104</volume>
<fpage>27</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="pmid">21696988</pub-id>
</element-citation>
</ref>
<ref id="ref28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolf</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Clinical issues and frequent questions about biotinidase deficiency</article-title>
<source/>Mol Genet Metab
          <year>2010</year>
<volume>100</volume>
<fpage>6</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="pmid">20129807</pub-id>
</element-citation>
</ref>
<ref id="ref29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leuzzi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Mastrangelo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Battini</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cioni</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Inborn errors of creatine metabolism and epilepsy</article-title>
<source/>Epilepsia
          <year>2013</year>
<volume>54</volume>
<fpage>217</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="pmid">23157605</pub-id>
</element-citation>
</ref>
<ref id="ref30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atwal</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Scaglia</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Molybdenum cofactor deficiency</article-title>
<source/>Mol Genet Metab
          <year>2016</year>
<volume>117</volume>
<fpage>1</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="pmid">26653176</pub-id>
</element-citation>
</ref>
<ref id="ref31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bayram</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Topcu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Karakaya</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yis</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Cakmakci</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ichida</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Molybdenum cofactor deficiency: Review of 12 cases (MoCD and review)</article-title>
<source/>Eur J Paediatr Neurol
          <year>2013</year>
<volume>171</volume>
<fpage>1</fpage>
<lpage>6</lpage>
</element-citation>
</ref>
<ref id="ref32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veldman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Santamaria-Araujo</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Sollazzo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pitt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gianello</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yaplito-Lee</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Successful treatment of molybdenum cofactor deficiency type A with cPMP</article-title>
<source/>Pediatrics
          <year>2010</year>
<volume>125</volume>
<fpage>e1249</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="pmid">20385644</pub-id>
</element-citation>
</ref>
<ref id="ref33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Giorgis</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Veggiotti</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>GLUT1 deficiency syndrome 2013: Current state of the art</article-title>
<source/>Seizure
          <year>2013</year>
<volume>22</volume>
<fpage>803</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="pmid">23890838</pub-id>
</element-citation>
</ref>
<ref id="ref34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kossoff</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Zupec-Kania</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Amark</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Ballaban-Gil</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Christina Bergqvist</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Blackford</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<collab>Practice Committee of the Child Neurology Society; International Ketogenic Diet Study Group</collab>
<article-title>Optimal clinical management of children receiving the ketogenic diet: Recommendations of the International Ketogenic Diet Study Group</article-title>
<source/>Epilepsia
          <year>2009</year>
<volume>50</volume>
<fpage>304</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="pmid">18823325</pub-id>
</element-citation>
</ref>
<ref id="ref35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mastrangelo</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Novel genes of early-onset epileptic encephalopathies: From genotype to phenotypes</article-title>
<source/>Pediatr Neurol
          <year>2015</year>
<volume>53</volume>
<fpage>119</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="pmid">26073591</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>